Efficacy and Safety of Stem Cell Mobilization with Etoposide +cytarabine Plus G-CSF in Poor Mobilizers with Relapsed or Refractory Lymphoma

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Aug 2

PMID 39091501

Authors

Zhijuan Zhu

Xiaofan Li

Xiaohong Yuan

Xianling Chen

Ting Lin

Xiangli Guo

Nainong Li

Affiliations

Soon will be listed here.

Abstract

Background: Autologous stem cell transplantation (ASCT) is a potentially curative strategy for relapse or refractory(r/r) aggressive lymphoma. However, a proportion of lymphoma patients who are at high risk of mobilization failure fail to mobilize stem cells and cannot proceed to ASCT. The aim of this study is to explore the efficacy and safety of Etoposide combined with Cytarabine (EA) plus G-CSF mobilization in poor mobilizers (PMs) with r/r aggressive lymphoma.

Methods: This retrospective study analyzed the outcomes of chemo-mobilization based on EA (Etoposide 0.1 g/m2, qd d1~3; AraC 0.5 g/m2, q12h d1~3) in 98 patients with r/r aggressive lymphoma. Of these, 39 patients met the criteria for predicted PMs as proposed by the Gruppo Italiano Trapianto di Midollo Osseo working group.

Results: Of the 39 PMs, 38(97.4%) patents harvested adequate mobilization (≥2×10 CD34+ cells/kg), while 31(79.5%) patients achieved optimal mobilization (≥5×10 CD34+ cells/kg). Overall, the mean number of CD34+ cells/kg collected was 17.99(range: 1.08~83.07) ×10 with an average of 1.4 apheresis sessions, and the number was 15.86(range: 0.37~83.07) ×10 for the first apheresis, respectively. A single apheresis procedure was sufficient to reach the target yield of adequate mobilization in 35(89.7%) PMs, while 76.9% of PMs achieved optimal collection within two apheresis sessions. We observed acceptable hematological toxicity and antibiotic usage exposure in 26 patients with a mean duration of 3.6 days. No grade 4 infection or mobilization-related mortality was recorded. Most patients underwent ASCT and achieved successful hematopoietic recovery with prompt engraftment duration, except for one NK/T-cell lymphoma patient who succumbed to severe septicemia after receiving conditioning chemotherapy.

Conclusion: Our findings indicate that EA plus G-CSF is an effective and tolerable CD34+ stem cell mobilization strategy for patients with r/r lymphoma, including those predicted to be PMs. This regimen could be an option for patients with r/r lymphoma, particularly those undergoing mobilization for salvage ASCT therapy.

References

Wood W, Whitley J, Moore D, Sharf A, Irons R, Rao K . Chemomobilization with Etoposide is Highly Effective in Patients with Multiple Myeloma and Overcomes the Effects of Age and Prior Therapy. Biol Blood Marrow Transplant. 2010; 17(1):141-6. DOI: 10.1016/j.bbmt.2010.06.021. View

Pavone V, Gaudio F, Console G, Vitolo U, Iacopino P, Guarini A . Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant. 2006; 37(8):719-24. DOI: 10.1038/sj.bmt.1705298. View

Ye P, Cheng Y, Lian J, Tong H, Li L, Guo Q . Etoposide combined with cytarabine and pegfilgrastim for poorly mobilizing patients with multiple myeloma and lymphoma: A prospective multicentre study. Br J Haematol. 2024; 204(6):2342-2350. DOI: 10.1111/bjh.19367. View

Oran B, Malek K, Sanchorawala V, Wright D, Quillen K, Finn K . Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transplant. 2005; 35(6):567-75. DOI: 10.1038/sj.bmt.1704826. View

Carral A, De La Rubia J, Martin G, Martinez J, Sanz G, Jarque I . Factors influencing hematopoietic recovery after autologous blood stem cell transplantation in patients with acute myeloblastic leukemia and with non-myeloid malignancies. Bone Marrow Transplant. 2002; 29(10):825-32. DOI: 10.1038/sj.bmt.1703566. View

Stiff P, Micallef I, Nademanee A, Stadtmauer E, Maziarz R, Bolwell B . Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma. Biol Blood Marrow Transplant. 2010; 17(8):1146-53. DOI: 10.1016/j.bbmt.2010.11.021. View

Alencar A, Moskowitz C . Autologous Stem Cell Transplantation in the Management of Relapsed Non-Hodgkin Lymphoma. J Clin Oncol. 2021; 39(5):467-475. DOI: 10.1200/JCO.20.01751. View

Pavone V, Gaudio F, Guarini A, Perrone T, Zonno A, Curci P . Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant. 2002; 29(4):285-90. DOI: 10.1038/sj.bmt.1703364. View

Giebel S, Kruzel T, Czerw T, Sadus-Wojciechowska M, Najda J, Chmielowska E . Intermediate-dose Ara-C plus G-CSF for stem cell mobilization in patients with lymphoid malignancies, including predicted poor mobilizers. Bone Marrow Transplant. 2013; 48(7):915-21. DOI: 10.1038/bmt.2012.269. View

10.

Mohty M, Azar N, Chabannon C, Le Gouill S, Karlin L, Farina L . Plerixafor in poor mobilizers with non-Hodgkin's lymphoma: a multi-center time-motion analysis. Bone Marrow Transplant. 2017; 53(3):246-254. DOI: 10.1038/s41409-017-0033-0. View

11.

Sheppard D, Bredeson C, Allan D, Tay J . Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2012; 18(8):1191-203. DOI: 10.1016/j.bbmt.2012.01.008. View

12.

Maranzano M, Mead M . The role of transplantation in Hodgkin lymphoma. Front Oncol. 2023; 12:1054314. PMC: 9908991. DOI: 10.3389/fonc.2022.1054314. View

13.

Majhail N, Farnia S, Carpenter P, Champlin R, Crawford S, Marks D . Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015; 21(11):1863-1869. PMC: 4830270. DOI: 10.1016/j.bbmt.2015.07.032. View

14.

Partanen A, Turunen A, Valtola J, Pyorala M, Vasala K, Kuittinen O . Autologous stem cell transplantation in peripheral T-cell lymphoma: better mobilization of blood CD34 cells is associated with improved survival. Leuk Lymphoma. 2020; 61(12):3027-3029. DOI: 10.1080/10428194.2020.1789629. View

15.

Zucenka A, Peceliunas V, Maciutaite E, Chaleckaite J, Jakimaviciute R, Griskevicius L . Etoposide + Granulocyte Colony-Stimulating Factor and Optional Plerixafor in Patients Who Failed Chemomobilization with or without Plerixafor. Biol Blood Marrow Transplant. 2019; 25(7):1304-1311. DOI: 10.1016/j.bbmt.2019.02.026. View

16.

Cheson B, Fisher R, Barrington S, Cavalli F, Schwartz L, Zucca E . Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27):3059-68. PMC: 4979083. DOI: 10.1200/JCO.2013.54.8800. View

17.

Steiner N, Gobel G, Mauser L, Muhlnikel L, Fischinger M, Kunz T . Poor Mobilizers in Lymphoma but Not Myeloma Patients Had Significantly Poorer Progression-Free Survival after Autologous Stem Cell Transplantation: Results of a Large Retrospective, Single-Center Observational Study. Cancers (Basel). 2023; 15(3). PMC: 9913576. DOI: 10.3390/cancers15030608. View

18.

Dipersio J, Stadtmauer E, Nademanee A, Micallef I, Stiff P, Kaufman J . Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009; 113(23):5720-6. DOI: 10.1182/blood-2008-08-174946. View

19.

Samara Y, Mei M . Autologous Stem Cell Transplantation in Hodgkin Lymphoma-Latest Advances in the Era of Novel Therapies. Cancers (Basel). 2022; 14(7). PMC: 8996995. DOI: 10.3390/cancers14071738. View

20.

Olivieri A, Marchetti M, Lemoli R, Tarella C, Iacone A, Lanza F . Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplant. 2011; 47(3):342-51. PMC: 3296914. DOI: 10.1038/bmt.2011.82. View